Nearly 370,000 bottles of duloxetine (the generic version of Cymbalta) were recently recalled. Distributed by Breckenridge Pharmaceutical, these delayed-release capsules were recalled because they contained levels of N-nitroso-duloxetine—a nitrosamine impurity linked to potential cancer risks over long-term exposure—that exceeded the FDA's acceptable limit
https://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-enforcement
No comments:
Post a Comment